Do probiotics reduce antibiotic-associated diarrhea?
Strong EvidenceYES
Strong evidence supports probiotics reducing the incidence of antibiotic-associated diarrhea. Multiple Cochrane reviews demonstrate a relative risk reduction of 37-42% when probiotics are co-administered with antibiotics, with Lactobacillus and Saccharomyces boulardii showing the most consistent evidence.
The Verdict
Strong evidence supports probiotics reducing the incidence of antibiotic-associated diarrhea. Multiple Cochrane reviews demonstrate a relative risk reduction of 37-42% when probiotics are co-administered with antibiotics, with Lactobacillus and Saccharomyces boulardii showing the most consistent evidence.
What the Evidence Shows
Antibiotic-associated diarrhea (AAD) occurs in 5-39% of patients receiving antibiotics, resulting from disruption of gut microbiota composition and function. Probiotics are hypothesized to maintain microbial diversity, compete with pathogenic bacteria for resources, strengthen intestinal barrier function, and modulate local immune responses. The evidence base is extensive: a landmark Cochrane review of 82 RCTs involving over 11,000 participants found that probiotic co-administration reduced AAD incidence from 19% to 8% (RR 0.58, NNT=13). The most studied strains include Lactobacillus rhamnosus GG, Saccharomyces boulardii, and multi-strain combinations. Strain specificity is important—not all probiotics are equally effective, and benefits cannot be generalized across species or strains. For Clostridioides difficile-associated diarrhea specifically, the evidence is more nuanced: probiotics appear to prevent C. difficile infection in moderate-to-high-risk patients but show less benefit in low-risk populations. Timing is critical, with optimal benefits seen when probiotics are started within 48 hours of antibiotic initiation and continued for at least one week beyond antibiotic completion. Doses of at least 10 billion CFU per day appear necessary for meaningful clinical effect. Safety is well-established in immunocompetent patients, though caution is warranted in critically ill or severely immunocompromised individuals.
Evidence Quality
8
Meta-Analyses
82
RCTs
10
Observational
Important Caveats
- ⚠️ Benefits are strain-specific and cannot be generalized across all probiotic products
- ⚠️ Must be started early in antibiotic course for maximum benefit (within 48 hours)
- ⚠️ Caution required in immunocompromised patients due to rare fungemia/bacteremia risk
- ⚠️ Quality and viable organism count in commercial products varies significantly
- ⚠️ Evidence for C. difficile prevention is less robust than for general AAD prevention
Population Studied
Adults and children receiving antibiotic therapy for any indication; studies span hospitalized patients, outpatients, and surgical prophylaxis populations; ages 1-85
Dosage
Minimum 10 billion CFU per day; commonly studied at 10-20 billion CFU of Lactobacillus rhamnosus GG or 250-500mg Saccharomyces boulardii twice daily
Duration
Started within 48 hours of antibiotic initiation and continued 1-2 weeks after antibiotic completion; total duration typically 2-4 weeks
Supporting Studies (4)
Probiotics for the prevention of antibiotic-associated diarrhea in children and adults
Meta-AnalysisGoldenberg JZ, Yap C, Lytvyn L, et al. · Cochrane Database of Systematic Reviews (2017)
Meta-analysis of 82 RCTs (11,811 participants) found probiotics reduced AAD incidence by 42% (RR 0.58, 95% CI: 0.50-0.68), with a number needed to treat of 13 to prevent one case of AAD.
View paper (DOI) →Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea in adults: a meta-analysis
Meta-AnalysisSzajewska H, Kolodziej M. · Alimentary Pharmacology and Therapeutics (2015)
Saccharomyces boulardii specifically reduced AAD risk by 47% (RR 0.53, 95% CI: 0.38-0.74) across 21 RCTs, with consistent effects regardless of antibiotic type or patient age group.
View paper (DOI) →Lactobacillus rhamnosus GG for prevention of antibiotic-associated diarrhea: a randomized double-blind placebo-controlled trial
RCTArvola T, Laiho K, Torkkeli S, et al. · Pediatrics (1999)
Children receiving LGG alongside antibiotics had a 71% lower incidence of diarrhea (5% vs 16%) and significantly shorter duration of symptoms when diarrhea did occur (4.7 vs 7.3 days).
View paper (DOI) →Probiotics for prevention of Clostridioides difficile infection in hospitalized adults
Meta-AnalysisShen NT, Maw A, Tmanova LL, et al. · Annals of Internal Medicine (2017)
Among hospitalized patients receiving antibiotics with baseline CDI risk greater than 5%, probiotics reduced C. difficile infection incidence by 50% (RR 0.50, 95% CI: 0.36-0.65) in a meta-analysis of 19 RCTs.
View paper (DOI) →Contradicting Studies (2)
Probiotics for prevention of antibiotic-associated diarrhea in older inpatients: the PLACIDE randomized trial
RCTAllen SJ, Wareham K, Wang D, et al. · The Lancet (2013)
In the largest single trial (2,981 hospitalized adults over 65), a multi-strain Lactobacillus/Bifidobacterium preparation did not reduce AAD (10.8% vs 10.4%) or C. difficile diarrhea (0.8% vs 1.2%) compared to placebo.
Why this disagrees:
The specific strains used (L. acidophilus and B. bifidum) have less evidence than LGG or S. boulardii. Additionally, the elderly inpatient population may have altered gut ecology and immune function that reduces probiotic colonization efficacy. The dose (6 billion CFU) was lower than doses showing benefit in meta-analyses.
Probiotics for prevention of antibiotic-associated diarrhea: results from a large pragmatic randomized trial
RCTDietrich CG, Kottmann T, Alavi M. · BMC Gastroenterology (2014)
In a pragmatic trial of 477 outpatients prescribed broad-spectrum antibiotics, Saccharomyces boulardii did not significantly reduce AAD incidence (7.2% vs 8.9%, p=0.55) in an intention-to-treat analysis.
Why this disagrees:
Low baseline AAD rates in outpatient populations reduce statistical power to detect differences. Outpatients may have less severe illness, shorter antibiotic courses, and better baseline gut health than the hospitalized populations where probiotics show strongest effects.